Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96SE0
UPID:
ABHD1_HUMAN
Alternative names:
Alpha/beta hydrolase domain-containing protein 1; Lung alpha/beta hydrolase 1
Alternative UPACC:
Q96SE0; B3KSF6; E9PDR9; Q05BY3; Q53SZ1; Q8IXQ7
Background:
Protein ABHD1, known as Alpha/beta hydrolase domain-containing protein 1 or Lung alpha/beta hydrolase 1, plays a crucial role in cellular processes. Its unique structure, characterized by the alpha/beta hydrolase domain, suggests a significant function in metabolic pathways. The exploration of ABHD1's enzymatic activities and substrate specificities is an active area of research, highlighting its potential in biochemical regulation.
Therapeutic significance:
Understanding the role of Protein ABHD1 could open doors to potential therapeutic strategies. While its direct involvement in diseases is yet to be established, the protein's enzymatic functions suggest its potential impact on metabolic disorders. Investigating ABHD1 further could unveil novel targets for drug development, offering new avenues for treating metabolic-related conditions.